AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

AN2 Therapeutics develops therapies for rare, chronic, and serious infectious diseases using their boron chemistry platform. Self-described as having a pipeline of novel boron-based compounds.

AN2 Therapeutics

AN2 Therapeutics | 1,734 followers on LinkedIn. Developing therapies for rare, chronic, and serious infectious diseases | AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs.  Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of infectious disease and improving global human health.   For more information, please visit www.an2therapeutics.com.

Sanjay Chanda

Executive Director, Clinical Operations

Kevin O'Shea

CEO & Co-Founder at AN2 Therapeutics

Eric Easom

Chief Financial Officer | Board Member

Stephanie Wong

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics supports the companionship that pets provide. Earlier this week we welcomed Taiko, Hiero, Niall, Blue, Piper, Peanut, Lizzie, and Elroy to our offices in Menlo Park.

Back from #ATS2024 ! We’re excited to have connected with healthcare professionals and clinicians supporting patients with rare, chronic and serious pulmonary diseases. #ATS

April 14 is #WorldChagasDay . We take this important opportunity to draw attention to this neglected disease that affects ~6 to 7 million people globally. We are proud to advance our preclinical drug candidate AN2-502998 (formerly AN15368) as a potential new treatment for patients with #ChagasDisease .

Today is #WorldNTDDay , a day where we raise awareness for the neglected tropical diseases that affect the world’s most vulnerable populations. At AN2 we have a passion for addressing the challenges of infectious diseases and improving global human health. #WorldNTDDay #research #Chagas #neglectedtropicaldiseases

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses	287.27K -
general and administrative expenses	1.73K -	1.26M 72,852.71%	4.67M 269.01%	12.75M 173.16%	14.76M 15.79%
selling general and administrative expenses	289K -	1.26M 337.72%	4.67M 269.01%	12.75M 173.16%	14.76M 15.79%
research and development expenses	4.89M -	6.02M 23.11%	16.91M 180.88%	29.51M 74.56%	54.87M 85.93%
other expenses		-6.32M -	-38K 99.40%	-45K 18.42%
cost and expenses	5.18M -	7.28M 40.67%	21.57M 196.18%	42.26M 95.89%	69.64M 64.77%
operating expenses	5.18M -	7.28M 40.67%	21.57M 196.18%	42.26M 95.89%	69.64M 64.77%
interest expense				514K -
ebitda	-5.18M -	-7.28M 40.67%	-21.57M 196.18%	-42.26M 95.89%	-69.64M 64.77%
operating income	-5.18M -	-7.28M 40.67%	-21.57M 196.18%	-42.26M 95.89%	-69.64M 64.77%
depreciation and amortization	31.07K -
total other income expenses net	-457K -	-6.32M 1,282.71%	31K 100.49%	1.31M 4,112.90%	4.90M 275.42%
income before tax	-5.63M -	-13.60M 141.40%	-21.54M 58.37%	-40.96M 90.11%	-64.73M 58.05%
income tax expense	-31.07K -	-3K 90.34%	-69K 2,200%	514K 844.93%
net income	-5.63M -	-13.60M 141.35%	-21.47M 57.90%	-41.47M 93.12%	-64.73M 56.09%
weighted average shs out	18.74M -	14.05M 25.04%	18.14M 29.13%	15.34M 15.43%	23.60M 53.85%
weighted average shs out dil	18.74M -	14.05M 25.04%	18.14M 29.13%	15.34M 15.43%	23.60M 53.85%
eps	-0.30 -	-0.97 223.33%	-1.18 21.65%	-2.70 128.81%	-2.74 1.48%
epsdiluted	-0.30 -	-0.97 223.33%	-1.18 21.65%	-2.70 128.81%	-2.74 1.48%

COM:AN2THERAPEUTICS

AN2 Therapeutics

Last Close

1.23

22/11 21:00

Market Cap

77.56M

Beta: -

Volume Today

1.25M

Avg: -

Preview